156 related articles for article (PubMed ID: 26222866)
1. Brain Metabolism of Less-Educated Patients With Alzheimer Dementia Studied by Positron Emission Tomography.
Huang YC; Yen PS; Wu ST; Chen JT; Hung GU; Kao CH; Chen TY; Ho FM
Medicine (Baltimore); 2015 Jul; 94(30):e1252. PubMed ID: 26222866
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease.
Liguori C; Chiaravalloti A; Sancesario G; Stefani A; Sancesario GM; Mercuri NB; Schillaci O; Pierantozzi M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2040-9. PubMed ID: 27221635
[TBL] [Abstract][Full Text] [Related]
3. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
4. Impaired cerebral glucose metabolism in prodromal Alzheimer's disease differs by regional intensity normalization.
Küntzelmann A; Guenther T; Haberkorn U; Essig M; Giesel F; Henze R; Schroeter ML; Schröder J; Schönknecht P
Neurosci Lett; 2013 Feb; 534():12-7. PubMed ID: 23182881
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
Mosconi L; Mistur R; Switalski R; Tsui WH; Glodzik L; Li Y; Pirraglia E; De Santi S; Reisberg B; Wisniewski T; de Leon MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):811-22. PubMed ID: 19142633
[TBL] [Abstract][Full Text] [Related]
6. Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD.
Beretta L; Caminiti SP; Santangelo R; Magnani G; Ferrari-Pellegrini F; Caffarra P; Perani D
Neuropsychologia; 2019 Oct; 133():107174. PubMed ID: 31446008
[TBL] [Abstract][Full Text] [Related]
7. [Measurement of regional cerebral metabolism rate of glucose in patients with Alzheimer's disease in different levels of severity].
Xiao SF; Cao QY; Xue HB; Liu YC; Zuo CT; Jiang KD; Zhang MY
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2975-9. PubMed ID: 16324383
[TBL] [Abstract][Full Text] [Related]
8. How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
Carapelle E; Serra L; Modoni S; Falcone M; Caltagirone C; Bozzali M; Specchio LM; Avolio C
Medicine (Baltimore); 2017 Apr; 96(16):e5876. PubMed ID: 28422821
[TBL] [Abstract][Full Text] [Related]
9. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of therapeutic response to donepezil by positron emission tomography.
Shimada A; Hashimoto H; Kawabe J; Higashiyama S; Kai T; Kataoka K; Tagawa R; Kawarada Y; Nakanishi A; Inoue K; Shiomi S; Kiriike N
Osaka City Med J; 2011 Jun; 57(1):11-9. PubMed ID: 22106763
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
[TBL] [Abstract][Full Text] [Related]
12. Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia.
Castellano CA; Nugent S; Paquet N; Tremblay S; Bocti C; Lacombe G; Imbeault H; Turcotte É; Fulop T; Cunnane SC
J Alzheimers Dis; 2015; 43(4):1343-53. PubMed ID: 25147107
[TBL] [Abstract][Full Text] [Related]
13. Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.
Hunt A; Schönknecht P; Henze M; Seidl U; Haberkorn U; Schröder J
Psychiatry Res; 2007 Jul; 155(2):147-54. PubMed ID: 17524628
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography metabolic correlates of apathy in Alzheimer disease.
Marshall GA; Monserratt L; Harwood D; Mandelkern M; Cummings JL; Sultzer DL
Arch Neurol; 2007 Jul; 64(7):1015-20. PubMed ID: 17620493
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
16. The functional neuroanatomy of verbal memory in Alzheimer's disease: [
Staffaroni AM; Melrose RJ; Leskin LP; Riskin-Jones H; Harwood D; Mandelkern M; Sultzer DL
J Clin Exp Neuropsychol; 2017 Sep; 39(7):682-693. PubMed ID: 27876444
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the normative profile of 18F-FDG PET brain imaging: sex difference, aging effect, and cognitive reserve.
Yoshizawa H; Gazes Y; Stern Y; Miyata Y; Uchiyama S
Psychiatry Res; 2014 Jan; 221(1):78-85. PubMed ID: 24262800
[TBL] [Abstract][Full Text] [Related]
18. On the multivariate nature of brain metabolic impairment in Alzheimer's disease.
Salmon E; Kerrouche N; Perani D; Lekeu F; Holthoff V; Beuthien-Baumann B; Sorbi S; Lemaire C; Collette F; Herholz K
Neurobiol Aging; 2009 Feb; 30(2):186-97. PubMed ID: 17651869
[TBL] [Abstract][Full Text] [Related]
19. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease.
Haense C; Buerger K; Kalbe E; Drzezga A; Teipel SJ; Markiewicz P; Herholz K; Heiss WD; Hampel H
Eur J Neurol; 2008 Nov; 15(11):1155-62. PubMed ID: 18803648
[TBL] [Abstract][Full Text] [Related]
20. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
